Coronaviruses are enveloped, positive-stranded RNA viruses that contain the largest
known RNA genomes to date. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
continues to circulate in the human population, multiple mutations have accumulated
over time, which may affect its transmission, virulence and antigenicity. Neutralizing
antibodies (NAbs) elicited by natural infection or vaccination are likely to be a
key immune correlate for protection against SARS-CoV-2 infection. A decline in the
antibody response to SARS-CoV-2 in convalescent individuals and reinfections by different
viral variants have been reported.
1–3
It is therefore important to gain insights into the infectivity and antigenicity of
SARS-CoV-2 variants.
Spike-specific antibodies contribute the majority of the neutralizing activity in
most convalescent human sera. Two SARS-CoV-2 variants, N501Y.V1 (also known as B.1.1.7
lineage or VOC-202012/01) and N501Y.V2 (B.1.351 lineage), reported from the United
Kingdom and South Africa, respectively, contain several mutations in the receptor-binding
domain (RBD) of Spike and are of particular concern. To address the infectivity and
neutralization escape phenotypes potentially caused by these mutations, we used the
SARS-CoV-2 pseudovirus system to compare the viral infectivity as well as the neutralization
activities of convalescent sera and monoclonal antibodies (mAbs) against SARS-CoV-2
variants.
The blood samples (n = 40) of 20 patients with COVID-19 obtained in February and October
2020 in Chongqing were previously described.
2
Eight RBD-specific mAbs with neutralizing capability against SARS-CoV-2 were obtained
from the blood samples of COVID-19 convalescent patients.
4
DNA sequences encoding the reference strain wild-type (WT) and mutant Spike proteins
of SARS-CoV-2 were codon-optimized and synthesized by Sino Biological Inc. (Beijing,
China) and GenScript Inc. (Nanjing, China). Using a luciferase-expressing lentiviral
pseudotype system, we expressed WT and N501Y.V1 (variant 1) and N501Y.V2 (variant
2) mutant Spike proteins in enveloped virions. NAbs were measured by pseudovirus-based
assays in 293T-ACE2 cells. The inhibitory dose (ID50) was calculated based on the
titers of NAbs.
First, the infectivity of pseudotyped viral particles was measured by luciferase assay
as previously described.
5
As shown in Fig. 1a, the entry efficiencies of Spike pseudotyped viruses bearing the
N501Y variant 1 or variant 2 mutant were ~3 to 4.4 times higher than that of the WT
pseudovirus when viral input was normalized, suggesting that these spike variants
promote the infectivity of SARS-CoV-2. Then, we assessed the neutralizing efficacy
of 40 convalescent serum samples from 20 individuals at two time points with a pseudovirus
neutralization assay. At follow-up time point 1, corresponding to a median of 25 days
(range 5–33 days) post symptom onset, most sera were significantly less effective
than the WT pseudovirus in neutralizing the N501Y variant 1 and variant 2 (Fig. 1b).
The mean NAb titers were 825 for WT, 343 for variant 1, and 148 for variant 2. The
neutralizing activity of two samples against N501Y.V1 was reduced by greater than
tenfold. Notably, the NAb titers of six samples (30%) decreased below the threshold
against variant 2 (Fig. 1b). At ~8 months post symptom onset (follow-up time point
2), 17 samples of 20 participants (85%) retained titers of ID50 > 40 against WT pseudovirus,
whereas the NAb titers of 8 samples (40%) and 18 samples (90%) decreased below the
threshold against N501Y variant 1 and variant 2, respectively (Fig. 1c). These data
indicate that N501Y variant 1 and variant 2 escape neutralizing antibodies in some
COVID-19 convalescent sera.
Fig. 1
Neutralizing activities of convalescent sera and monoclonal antibodies against SARS-CoV-2
variants.
a Infectivity of WT and variant pseudoviruses assessed in 293T-ACE2 and A549-ACE2
cells. Cells were inoculated with equivalent doses of each pseudotyped virus. WT,
wild-type Spike (GenBank: QHD43416) pseudotyped virus; Variant 1, N501Y.V1 mutant
Spike pseudotyped virus (containing the H60/V70 and Y144 deletions and N501Y, A570D,
D614G, P681H, T716I, S982A, and D1118H mutations); Variant 2, N501Y.V2 mutant Spike
pseudotyped virus (containing the K417N, E484K, N501Y, and D614G mutations). Neutralization
of WT and variant pseudoviruses by convalescent sera. Pseudovirus-based neutralization
assays were performed to detect neutralizing antibody (NAb) titers against SARS-CoV-2.
The thresholds of detection were 1:40 of the ID50. Twenty sera (indicated by circles)
were drawn 5 to 33 days post symptom onset (b); 20 sera (indicated by triangles) were
drawn ~8 months post symptom onset (c). The half-maximal inhibitory concentrations
(IC50) for tested monoclonal antibodies (mAbs) against pseudoviruses (d) and representative
neutralization curves (e)
In addition, we assessed the impact of these variants on the neutralizing activity
of human mAbs isolated from COVID-19 convalescent patients. All eight antibodies potently
neutralized the WT pseudovirus, while two mAbs (CQ016 and CQ045) were only minimally
affected by the variants. However, the neutralization activities of the six other
mAbs were reduced or abolished by either N501Y variant 1 or variant 2 (Fig. 1d). Among
them, three mAbs were threefold or more less effective against N501Y.V1 and five against
N501Y.V2 (Fig. 1d). Notably, two mAbs (CQ026 and CQ038) showed no neutralizing activity
against N501Y.V2. Moreover, variant 2 reduced the neutralization sensitivity with
CQ046 by 26-fold, which showed the most potent activity against WT pseudovirus. The
IC50 of the mAb CQ046 increased from 7.4 ng/ml (WT) to 194 ng/ml (variant 2) (Fig. 1e).
Overall, both N501Y variant 1 and variant 2 reduced neutralization sensitivity to
most mAbs tested, while N501Y.V2 even abrogated the neutralizing activity of two mAbs.
Our findings indicated that N501Y variant 1 and variant 2 increase viral infectivity
compared to that of the reference strain in vitro. Notably, both N501Y variant 1 and
variant 2 contain the D614G and N501Y mutations in the Spike protein. The findings
that variant 1 and variant 2 enhanced the infectivity of SARS-CoV-2 in vitro are highly
consistent with previous studies, which demonstrated that D614G and N501Y mutations
enhanced the fitness and transmissibility of the virus, as evidenced by structure
analysis and the increased number of clinical cases.
6,7
Another key question is whether some mutations may enable immune evasion. It has been
reported that neutralization escape mutants can be selected by passaging virus in
the presence of NAbs.
8
Consistent with other recent studies,
9,10
we observed that two naturally occurring SARS-CoV-2 variants, N501Y variant 1 and
variant 2, were more resistant than WT virus to neutralization by some mAbs and convalescent
sera from patients who were infected in mid- to late- January 2020 when a “first-wave”
virus was circulating in China. Consistently, Spike variants with the H60/V70 deletion
or E484K mutation have significantly reduced susceptibility to neutralization by the
polyclonal serum antibodies of some individuals.
11,12
Whether these patients are at high risk of reinfection with ‘second-wave’ variants
should be explored in further studies. It is also urgent to assess the effectiveness
of currently authorized vaccines against these variants.
Collectively, this study will be helpful for understanding SARS-CoV-2 infectivity
and for the design of vaccines against COVID-19. Given the evolving nature of the
SARS-CoV-2 RNA genome, antibody therapeutics and vaccine development require further
considerations to accommodate mutations in Spike that may affect the antigenicity
of the virus. Limitations of this study include its small sample size and the use
of a nonreplicating pseudovirus system. Therefore, further studies with authentic
SARS-CoV-2 viruses are required.
Supplementary information
Supplementary information